Chronic Hepatitis: Symptoms, Types, Diagnosis and Treatment

The liver is an organ of extraordinary patience. It has no pain receptors, an enormous functional reserve, and a remarkable capacity for self-repair even when substantially damaged. This is precisely why chronic hepatitis — liver inflammation lasting more than six months — progresses silently for years, and the first noticeable symptoms typically appear only when a significant portion of tissue has already been replaced by scar. Chronic hepatitis is not a single disease but a family of conditions with different causes yet a common outcome when untreated: cirrhosis and its complications. Here is how each variant develops, how to recognise them, and how they are treated.

What Is Chronic Hepatitis and How It Differs from Acute

Acute hepatitis is a short-lived liver inflammation that resolves on its own in most cases within several months. Chronic hepatitis is inflammation that persists beyond six months and does not resolve without treatment. The six-month threshold is a clinical convention, but an internationally accepted one: within this period it becomes clear whether the disease is subsiding or becoming established.

In chronic inflammation, hepatocytes — liver cells — die and are replaced by connective tissue. This process is called fibrosis. While fibrosis is mild (F0–F1 on the METAVIR scale), liver function is largely preserved. As it advances to significant fibrosis (F3) and cirrhosis (F4), functional reserve is exhausted: the liver can no longer adequately synthesise proteins, detoxify the blood, or regulate clotting.

The defining feature of chronic hepatitis is the dissociation between inflammatory activity and how the patient feels. High-grade inflammation can coexist with complete absence of symptoms. This means that feeling well is not an argument against the diagnosis — and not a reason to defer testing.

Types of Chronic Hepatitis: Causes and Mechanisms

"Chronic hepatitis" covers several fundamentally different diseases requiring different treatments. Identifying the type is the mandatory first step.

Viral hepatitis B (HBV) — transmitted through blood, sexually, and from mother to child during delivery. Around 250 million people worldwide are chronic carriers. The virus integrates into hepatocyte DNA and can persist for life. Without treatment, 20–30% of chronic carriers develop cirrhosis over 20–30 years.

Viral hepatitis C (HCV) — transmitted primarily through blood (injecting drug use, blood transfusions before 1992, non-sterile medical procedures). Becomes chronic in 75–85% of acute infections. A landmark development of the past decade: hepatitis C is now fully curable — direct-acting antiviral combinations achieve a sustained virological response in 95–99% of patients.

Autoimmune hepatitis (AIH) — the immune system attacks its own hepatocytes. Cause unknown; more common in women. Characterised by markedly elevated transaminases, hypergammaglobulinaemia, and specific autoantibodies (ANA, SMA, anti-LKM-1). Responds well to immunosuppression with prednisolone and azathioprine.

Toxic (drug-induced) hepatitis — direct liver injury by chemical agents: alcohol, medications, herbal supplements. Alcoholic hepatitis progresses to alcoholic cirrhosis if drinking continues. Drug-induced hepatitis can be caused by paracetamol (at high doses), methotrexate, amiodarone, isoniazid, nitrofurantoin, and many others.

Non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH) — the fastest-growing type worldwide. Fat accumulates in hepatocytes, triggering inflammation. Strongly associated with obesity, insulin resistance and type 2 diabetes. In 20–30% of NASH patients fibrosis develops; some progress to cirrhosis.

Symptoms of Chronic Hepatitis

Most people with chronic hepatitis have no symptoms for years — or symptoms so nonspecific that they raise no concern.

Early and nonspecific signs:

• Chronic fatigue without another explanation — the most frequent symptom
• Heaviness or discomfort in the right upper abdomen — especially after fatty food or alcohol
• Reduced appetite and mild nausea
• Decreased alcohol tolerance

Signs of more significant liver damage:

• Jaundice — yellow tinge of skin and sclerae; appears when bilirubin excretion is impaired
• Dark urine ("beer-coloured") and pale stools — impaired bile flow
• Skin itching — bile acids retained in the blood during cholestasis
• Unexplained weight loss

Signs of established cirrhosis:

• Ascites — fluid accumulation in the abdomen (distended, tense belly)
• Leg oedema
• Palmar erythema and spider naevi on the skin
• Splenomegaly
• Bleeding from oesophageal varices — a life-threatening complication

By the time cirrhosis becomes symptomatic, reversing the process is no longer possible — only halting further progression.

Diagnosis: Blood Tests and Investigations

Diagnosing chronic hepatitis involves three parallel tasks: confirming liver damage, identifying its cause, and assessing the degree of fibrosis.

ALT (alanine aminotransferase) — the most specific marker of hepatocellular damage. ALT elevation above the upper limit of normal is a warning signal requiring further investigation. In chronic hepatitis, ALT may be persistently mildly elevated or fluctuate.

AST (aspartate aminotransferase) — rises in parallel with ALT in hepatocellular injury. An AST:ALT ratio (de Ritis ratio) > 2 is characteristic of alcoholic hepatitis; in viral hepatitis this ratio is usually below 1.

Alkaline phosphatase (ALP) — a marker of cholestasis and bile duct involvement. In primary biliary cholangitis and primary sclerosing cholangitis, ALP is disproportionately elevated.

GGT (gamma-glutamyltransferase) — a sensitive marker of liver pathology, particularly toxic and alcoholic components. Isolated GGT elevation with normal transaminases often points to early NAFLD or alcohol overuse.

Bilirubin — rises when hepatocyte uptake and excretion are impaired. Clinical jaundice becomes visible above 35–40 µmol/L. Sustained elevation of direct (conjugated) bilirubin indicates significant cholestasis or severe hepatocellular damage.

Albumin — synthesised exclusively in the liver. A fall below the normal range in chronic hepatitis signals developing hepatic insufficiency and advanced fibrosis. A normal albumin level in chronic hepatitis is a favourable prognostic sign.

All the above markers form part of a standard liver function test panel — a comprehensive assessment of overall hepatic function.

When pancreatic inflammation is suspected — common with gallstone disease or alcohol-related injury — amylase and lipase are additionally measured.

Serological and molecular tests:

• HBsAg, anti-HBc IgG, HBV DNA — for hepatitis B
• Anti-HCV, HCV RNA — for hepatitis C
• ANA, SMA, anti-LKM-1, IgG — for autoimmune hepatitis

Fibrosis assessment:

• Liver ultrasound — evaluates structure, size, presence of ascites
• Transient elastography (FibroScan) — non-invasive measurement of liver stiffness; gold standard for non-invasive fibrosis staging
• Liver biopsy — invasive but most precise; used when non-invasive results are inconclusive

Treating Chronic Hepatitis

Treatment differs fundamentally by cause — which is precisely why identifying the type comes first.

Viral hepatitis B: The goal is to suppress viral replication and prevent progression to cirrhosis. Two drug classes are used:

• Nucleoside/nucleotide analogues (entecavir, tenofovir) — taken long-term, often lifelong; suppress viral load to undetectable levels
• Pegylated interferon-alpha — a 48-week course; a small proportion of patients achieve functional cure (loss of HBsAg)

Viral hepatitis C: Complete cure is achievable in 95–99% of patients with modern direct-acting antivirals (DAAs): glecaprevir/pibrentasvir or sofosbuvir/velpatasvir combinations. Treatment duration is 8–12 weeks. After achieving a sustained virological response (SVR), the risk of cirrhosis falls sharply, and fibrosis may regress even when already present.

Autoimmune hepatitis: Immunosuppressive therapy: high-dose prednisolone tapered gradually, plus azathioprine. With proper treatment, remission is achieved in 80–90% of patients. Treatment is often lifelong — withdrawal may be attempted only after sustained biochemical remission.

Toxic (alcoholic) hepatitis: The only proven effective intervention is removing the cause. Complete alcohol abstinence in alcoholic hepatitis halts progression and often leads to partial fibrosis regression. Glucocorticoids are used short-term in severe alcoholic hepatitis.

NAFLD/NASH: Treatment targets the underlying metabolic disturbances:

• Weight loss of 7–10% from baseline reduces steatosis grade and inflammation
• Physical activity independently improves histological findings regardless of weight change
• Control of diabetes and dyslipidaemia is mandatory
• Resmetirom — the first FDA-approved drug for NASH with F2–F3 fibrosis (2024) — represents a new specific therapeutic option

Complications of Chronic Hepatitis

Two major outcomes of untreated chronic hepatitis are cirrhosis and hepatocellular carcinoma (HCC).

Cirrhosis — the end stage of fibrosis, in which normal liver architecture is completely replaced by scar tissue and regenerative nodules. It develops on average over 20–30 years of chronic hepatitis, but faster with high inflammatory activity or additional hepatotoxic factors. Cirrhosis complications include portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, and spontaneous bacterial peritonitis.

Hepatocellular carcinoma (HCC) — primary liver cancer, developing predominantly on a cirrhotic background. Risk is especially high with hepatitis B and C. HCC screening — liver ultrasound every 6 months with alpha-fetoprotein — is recommended for all patients with cirrhosis.

A critical point: even at F3–F4 fibrosis (cirrhosis), treating the underlying cause of hepatitis reduces the risk of HCC and decompensation. This means it is never too late to start — but earlier is always better.

When to See a Doctor Urgently

Most chronic hepatitis situations are managed electively. However, several presentations require emergency assessment:

• Sudden worsening of jaundice — a rapid increase in jaundice in known chronic hepatitis may indicate acute decompensation or superinfection with another hepatotropic virus
• Rapidly increasing abdominal girth — new or rapidly expanding ascites; risk of spontaneous bacterial peritonitis
• Bloody vomiting or black tarry stools — variceal bleeding from oesophageal or gastric varices; immediately life-threatening
• Confusion or disorientation — a sign of hepatic encephalopathy
• ALT or AST above 10 times the upper limit of normal on a routine test — even without symptoms, requires prompt clinical review

On an elective basis: any incidentally discovered elevation of liver enzymes, the presence of risk factors (history of viral hepatitis, alcohol overuse, obesity, diabetes, long-term hepatotoxic medications), or a family history of liver disease.

Chronic hepatitis is a disease that can in most cases be halted. Early detection and appropriately targeted treatment preserve liver function and prevent cirrhosis. The liver is forgiving — but only when given the opportunity in time.

This article is for informational purposes only. Diagnosis and treatment are the responsibility of a gastroenterologist or hepatologist.